IRCT20180618040127N3招募中3 期
Evaluation of Teriflunomide’s safety and effect on clinical signs, inflammatory and viral factors in patients with HTLV-1-induced myelopathy
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 no limit（—）
- 性别
- All
入选标准
- •Positive serology for Human T-cell Lymphotropic Virus Type-1 (HTLV-1)
- •Occurrence of spastic paraparesia
- •Existence of anti HTLV-1 antibody in cerebrospinal fluid
- •Rule out of other etiologies of spastic paraparesia
- •Motor Disability Grading (MDG) less than 9
- •Informed consent for participating in the study
排除标准
- •Existence of other active and latent infections include of old or active tuberculosis or hepatitis
- •Receiving other drug which influence immune system
- •Severe renal dysfunction
- •Married women of childbearing age who do not use safe contraception
研究者
相似试验
招募中
不适用
In-vivo Bioequivalence Test of Teriflunomide® tablet with brand drugs (AUBAGIO® 14 mg Genzyme, Germany).IRCT20200105046010N25Aburayhan Pharmaceutical Company24
招募中
不适用
In-vivo Bioequivalence Test of Teriflunomide tablets with brand drug (AUBAGIO® 14 mg, Genzyme, Germany)Bio equivalence test.IRCT20200105046010N47Abidi Pharmaceutical Company24
已完成
4 期
Evaluation of efficacy and safety of Terbinafine, Fluconazole and Itraconazole in skin fungal infectionsCTRI/2018/04/013303Dr D Aruna
已完成
4 期
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) PatientsMultiple SclerosisNCT01895335Sanofi1,001
已完成
2 期
Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With RelapsesMultiple SclerosisNCT01487096Sanofi179